In vivo drug discovery for β-cell proliferation in diabetes
In a examine printed in Nature Metabolism, researchers on the division of Cell and Molecular Biology developed a novel method to establish small molecules that may make insulin-producing β-cells divide.
Olov Andersson and Jeremie Charbord explains: “Diabetes is characterised by the progressive lack of practical β-cells. One attainable strategy to curing diabetes is to generate new β-cells in situ to replenish the pool of β-cells. β-cell proliferation expands the β-cell mass principally throughout growth but additionally underneath sure hyperglycemic circumstances in maturity, a course of that would doubtlessly be used for β-cell regeneration in diabetes.
“To display screen for chemical compounds that may induce β-cell proliferation, we developed a novel assay in zebrafish primarily based on the fluorescence ubiquitination cell-cycle indicator (FUCCI) technique, during which the S/G2/M marker geminin is fused to a fluorescent protein. As a substitute of fusing geminin to a fluorescent protein, we fused it to a luciferase protein and expressed it underneath the management of the insulin promoter to particularly report β-cell proliferation in vivo in a high-throughput method. We named this assay LUCCI (for Luminescence Ubiquitination-based Cell Cycle Indicator) and used it to arrange a high-throughput chemical display screen in transgenic zebrafish. On this manner, we recognized a kinase inhibitor that potently stimulates β-cell proliferation, and confirmed this impact in mouse and human β-cells to ensure the impact is conserved throughout species.
“Utilizing single-cell transcriptomic analyses of β-cells, we discovered that the kinase inhibitor induced an unfolded-protein response previous to cell-cycle entry, that’s, a light and transient wave of unfolded protein response that was mandatory for proliferation to happen. Importantly, this wave was not related to a rise in insulin expression, which in diabetes might be related to robust and protracted activation of a maladaptive unfolded protein response. Our findings counsel a novel idea during which a small molecule can transiently activate the unfolded-protein response to induce β-cell proliferation—a mechanism that may be leveraged to develop the variety of β-cells in diabetes.”
Dietary amino acid determines the destiny of most cancers cells
Jérémie Charbord et al, In vivo display screen identifies a SIK inhibitor that induces β cell proliferation by means of a transient UPR, Nature Metabolism (2021). DOI: 10.1038/s42255-021-00391-x
In vivo drug discovery for β-cell proliferation in diabetes (2021, Could 26)
retrieved 31 Could 2021
This doc is topic to copyright. Aside from any truthful dealing for the aim of personal examine or analysis, no
half could also be reproduced with out the written permission. The content material is supplied for info functions solely.